NWBO made the decision to move ahead without the covering of ECA guidance being written in stone in the manner that was required to avoid creating potential legal liability for updating clinicaltrials.gov before explaining ECA use and need to move to other endpoints publicly. The update was not a consequence of being an afterthought as some have stated. The bears planned for this opportunity and some fell victim while others made out well by being able to increase the size of their position. What is interesting about that day is that the price held at the last remaining unbroken uptrend set after the true long term double bottom of about $.01 up per month. Amazing how well targets can be hit. Now the next targets are going to be in that new high range also built into the charts which is based on minimum expected initial production capacity, ramp and potential partnership value. Best wishes.